The cGAS-STING pathway mediates induction of CXCL9/10 in DCs; therefore, STING agonists are potential as therapeutic agents [43, 44] for activating DCs and recruiting T lymphocytes in tumor treatment. The gene discussed is CXCL9; the disease is neoplasm.